Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Asthma, nasal polyposis and ulcerative colitis: a new perspective.

× No keyword cloud information.

5 in total

1. Bioactive Components and Potential Mechanism Prediction of Kui Jie Kang against Ulcerative Colitis via Systematic Pharmacology and UPLC-QE-MS Analysis.

Authors: Jinbiao He; Chunping Wan; Xiaosi Li; Zishu Zhang; Yu Yang; Huaning Wang; Yan Qi
Journal: Evid Based Complement Alternat Med Date: 2022-06-21 Impact factor: 2.650

2. Uygur medicine Xipayi Kui Jie'an affects gene expression profiles in intestinal tissue lesions in a rat model of ulcerative colitis.

Authors: Kurexi Yunusi; Jingping Zhang; Li Zhong; Gulinisha Mosha; Ajiguli Nuermaimaiti; Mairipaiti Abudula; Halmurat Upur
Journal: BMC Complement Altern Med Date: 2015-05-22 Impact factor: 3.659

3. Qingchang Wenzhong Decoction Attenuates DSS-Induced Colitis in Rats by Reducing Inflammation and Improving Intestinal Barrier Function via Upregulating the MSP/RON Signalling Pathway.

Authors: Tangyou Mao; Junxiang Li; Lijuan Liu; Weihan Zhao; Yuyue Liu; Kangli Gao; Yi Guo; Tianhong Xie; Ningfei Li; Rui Shi
Journal: Evid Based Complement Alternat Med Date: 2017-10-12 Impact factor: 2.629

4. A Systems Pharmacology Approach to Determine Active Compounds and Action Mechanisms of Xipayi KuiJie'an enema for Treatment of Ulcerative colitis.

Authors: Wei Yu; Zhihong Li; Fei Long; Wen Chen; Yurong Geng; Zhiyong Xie; Meicun Yao; Bo Han; Teigang Liu
Journal: Sci Rep Date: 2017-04-26 Impact factor: 4.379

5. Simultaneous Determination of Ten Bioactive Components from Shenling Baizhu San in Rat Plasma by UHPLC-MS/MS: Application to a Comparative Pharmacokinetic Study in Normal and Two Models of Ulcerative Colitis Rats.

Authors: Xia Xu; Weiwei Wang; Yaxi Chen; Qiyun Zhang; Bingtao Li; Yiwen Zhong; Yu Tu; Wentong Zhang; Guoliang Xu; Li Jiang
Journal: Evid Based Complement Alternat Med Date: 2021-12-29 Impact factor: 2.629

5 in total